It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
Mesothelioma
A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001)
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Keytruda and Chemotherapy Improve Survival in Mesothelioma Patients
The U.S Food and Drug Administration has accepted a priority review for a new Supplemental Biologics License Application. This could be a new era in the management of pleural mesothelioma, leading to a better future for those diagnosed with the cancer. The review is looking for approval of Keytruda used[…]
Immune Checkpoint Inhibitors Can Improve Survival in Mesothelioma Patients
Malignant pleural mesothelioma is a rare cancer that is hard to treat. There is a poor prognosis for people diagnosed with mesothelioma, but there is hope in the form of immune checkpoint inhibitors. There could be a chance of better outcomes in mesothelioma patients. A new article in Open Respiratory[…]
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent / refractory pleural mesothelioma.
Delayed Care for Mesothelioma Could be Beneficial for Patients
Mesothelioma, a cancer mainly caused by asbestos, is very hard to treat. A new study wanted to see if treating mesothelioma immediately is the best option for certain patients. The study, which was published in Clinical Lung Cancer, looks at patients with inoperable pleural mesothelioma. The study compared patients who[…]
Surgery Improves Survival in Mesothelioma Patients
There is a debate about whether surgery for mesothelioma is beneficial. A new study was presented at the World Conference on Lung Cancer. The study looked at the survival of pleural mesothelioma patients who had different types of treatment. These included chemotherapy followed by surgery and chemotherapy only. The goal[…]
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma than methoxyamine and pemetrexed disodium.
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Primary Outcome Measures Number of participants treated with Alintegimod monotherapy with treatment related adverse events as assessed by CTCAEv5.0 Number of participants treated with Alintegimod in combination with treatment related adverse events as assessed by CTCAEv5.0 Define RPTDs for Alintegimod Secondary Outcome Measures Characterize Pharmacokinetics of Alintegimod monotherapy by measuring[…]
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Skip to content